ADI Launches the Alzheimer’s Disease Atlas
Access the world's first of its kind platform highlighting how countries diagnose, treat and support people living with dementia.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
Highlights from the National Dementia Plan Pan Regional Workshop 2026
Government representatives, dementia associations and WHO experts gathered in London to share progress, tackle challenges and strengthen collaboration on developing and implementing effective National Dementia Plans worldwide.
ADI submits statement on dementia and COVID-19 ahead of World Health Assembly
In advance of the 73rd World Health Assembly, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.
New blood test research for diagnosis of Alzheimer’s disease shows promising results
A new study in the Lancet Neurology has shown that blood phosphorylated tau 181 may be a promising biomarker for Alzheimer’s disease.
ADI welcomes new Associations and Board members
ADI welcomes three new Alzheimer associations, as well as new members to the ADI board.
ADI releases a position paper on COVID-19 and dementia
ADI releases a position paper on the difficult decisions people with dementia, their families and carers are having to make around hospital admission and triage during COVID-19.
COVID-19: Sharing experience and advice from ADI’s member association in China
Professor Huali Wang of Alzheimer's Disease Chinese (ADC) explains how China has addressed the specific challenges of people living with dementia during COVID-19.
Global Perspective for February 2020
ADI's Global Perspective for February 2020 now available.
Roche to end DIAN-TU-001 study for rare Autosomnal dominant Alzheimer’s disease
Roche announces end of DIAN-TU-001 study after it failed to meets its primary endpoint in people who are affected by early onset Autosomal dominant Alzheimer’s disease.
China approves first drug for mild to moderate Alzheimer’s in 17 years
hinese Pharmaceutical Company Green Valley announces their drug Oligomannate (GV-971) has been granted conditional approval for the treatment of "mild to moderate Alzheimer's disease".